160 related articles for article (PubMed ID: 30472042)
1. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Chu CY; Cheng CH; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
J Formos Med Assoc; 2019 Jul; 118(7):1129-1137. PubMed ID: 30472042
[TBL] [Abstract][Full Text] [Related]
2. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
[TBL] [Abstract][Full Text] [Related]
3. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
[TBL] [Abstract][Full Text] [Related]
4. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
5. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
[TBL] [Abstract][Full Text] [Related]
6. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
[TBL] [Abstract][Full Text] [Related]
7. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
9. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
10. Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
Ueda Y; Marusawa H; Kaido T; Ogura Y; Oike F; Mori A; Ogawa K; Yoshizawa A; Hatano E; Miyagawa-Hayashino A; Haga H; Egawa H; Takada Y; Uemoto S; Chiba T
J Viral Hepat; 2012 Jan; 19(1):32-8. PubMed ID: 21129128
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
12. Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.
Schvarcz R; Glaumann H; Reichard O; Weiland O
J Viral Hepat; 1999 May; 6(3):237-42. PubMed ID: 10607236
[TBL] [Abstract][Full Text] [Related]
13. Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.
Parise ER; de Oliveira AC; Conceição RD; Amaral AC; Leite K
Braz J Infect Dis; 2006 Apr; 10(2):78-81. PubMed ID: 16878256
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.
Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y
J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300
[TBL] [Abstract][Full Text] [Related]
15. Treatment of HCV in renal transplant patients with peginterferon and ribavirin: long-term follow-up.
Mak SK; Sin HK; Lo KY; Lo MW; Chan SF; Lo KC; Wong YY; Ho LY; Wong PN; Wong AKM
Clin Exp Nephrol; 2017 Oct; 21(5):764-770. PubMed ID: 28083764
[TBL] [Abstract][Full Text] [Related]
16. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
18. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
[TBL] [Abstract][Full Text] [Related]
19. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
20. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]